May 23, 2017
Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome
Media
May 23, 2017
New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients without Collateral Ventilation
May 22, 2017
Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn Odlander
May 22, 2017
BONESUPPORT™ Announces First Patient Enrolled in FORTIFY Trial with CERAMENT®|G, a novel injectable, antibiotic-eluting bone graft substitute
May 19, 2017
Safety Review Committee Approves the Continued Evaluation of the 20 MBq/kg Betalutin® with 100 mg/m2 Lilotomab Regimen in Phase 2 Cohort in NHL
May 19, 2017
Nexstim Plc Updates the Timeline for its Supplementary E-FIT Phase III Trial in Stroke Rehabilitation
May 19, 2017
Wilson Therapeutics to present at Bioequity Europe
May 18, 2017
Targovax ASA: ASCO abstract released
May 17, 2017
Wilson Therapeutics AB (publ) Interim Report January 1 – March 31, 2017
May 16, 2017
Nordic Nanovector ASA: Invitation to First Quarter 2017 Results Presentation and Webcast